Page last updated: 2024-08-22

platinum and etoposide

platinum has been researched along with etoposide in 94 studies

Research

Studies (94)

TimeframeStudies, this research(%)All Research%
pre-19903 (3.19)18.7374
1990's15 (15.96)18.2507
2000's5 (5.32)29.6817
2010's24 (25.53)24.3611
2020's47 (50.00)2.80

Authors

AuthorsStudies
Carter, SK; Muggia, FM; Rozencweig, M; Slavik, M1
Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T1
Bakri, YN; Ezzat, A; Pedersen, P1
Bacchi, M; Bassi, P; Belsanti, V; Bisagni, G; Boni, C; Cocconi, G; Lottici, R; Passalacqua, R; Tonato, M1
Einhorn, LH; Loehrer, PJ; Seitz, DE; Williams, SD1
Schwarz, MA; Snyder, RD1
Bosl, GJ; Motzer, RJ; Parker, RJ; Perera, F; Poirier, MC; Reed, E; Shamkhani, H; Tang, D; Tsai, WY1
de Boer-Dennert, M; Ma, J; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; van Ingen, HE; Verweij, J1
Frenkel, EP; Henner, WD; Mickey, BE; Neuwelt, EA; Wiliams, PC1
Turrisi, AT1
Hill, BT; Hosking, LK; Shellard, SA1
Dive, C; Evans, DL; Tilby, M1
Hoskins, PJ; Swenerton, KD1
Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W1
Jones, WB; Lewis, JL; Schneider, J; Shapiro, F1
Hayashi, N; Ikeba, K; Kinoshita, K; Ohokubo, T; Sodemoto, T; Takagi, A; Takeda, S; Yamamoto, T1
Berthiot, G; Coninx, P; Desoize, B; Dumont, P; Manot, L1
Kano, M; Watanabe, M1
Greco, FA1
Sugiyama, T1
Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M1
Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE1
Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P1
Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ1
Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L1
Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L1
Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Gaillard, R; Giroux, J; Goldwasser, F; Mir, O; Ropert, S1
Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M1
Buyukberber, S; Elkiran, ET; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M; Ozdemir, N; Ulas, A; Unal, O; Urakci, Z; Yaman, S1
Levy, B; Saxena, A; Schneider, BJ1
Ganti, AK; West, WW; Zhen, W1
Boikos, SA; Brahmer, JR; Ettinger, DS; Forde, PM; Giaccone, G; Hann, CL; Hooker, CM; Illei, PB; Kelly, RJ; Petrini, I; Rudin, CM; Yang, SC1
Hassan, U; Mozayani, B; Wong, NA1
Bunne, M; Fosså, SD; Gundersen, POM; Osnes, T; Skalleberg, J; Småstuen, MC; Solheim, O1
Chen, L; Chen, Y; Zhong, D1
Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ1
Fatima, I; Masood, M; Nisar, H; Sattar, A; Shahid, AB1
Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K1
Gourley, C1
Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F1
Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y1
Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P1
Goetze, TO1
Adjei, AA; Aubry, MC; Bertino, E; Dakhil, SR; Dy, GK; Lee Hann, C; Mandrekar, SJ; Molina, JR; Nieva, JJ; Sachs, BA; Schenk, EL; Schild, SE; Tan, AD; Wadsworth, TW1
Escriu, C; Sallam, M; Wong, H1
Balakrishnan, A; Kumar, P; Prasanna, BK1
Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC1
Chen, Y; Dvorkin, M; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Laud, PJ; Losonczy, G; Özgüroğlu, M; Patel, N; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Shire, N; Statsenko, G; Trukhin, D; Voitko, O1
Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L1
Ding, HY; Fang, L; Tong, YH; Xin, WX; Xu, GQ; Yang, GN; Zhang, B; Zhong, LK1
Chen, B; Lin, J; Peng, J; Xue, L1
Horita, N; Katakura, S; Takeshi, K1
Goldman, JW; Paz-Ares, L1
Xia, D; Xu, X; Yang, W; Zhang, Y1
Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W1
Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y1
Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X1
Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W1
Economidou, SC; Fotopoulos, G; Vrontis, K1
Abdel-Rahman, O; Koski, SL1
Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X1
Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inoue, Y; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Watanabe, H; Yasui, H1
Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O1
Chang, CH; Chang, YL; Chen, JS; Hsu, FM; Huang, YL; Lee, JM; Lin, CC; Ma, WL; Yang, JC1
Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X1
An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H1
Hara, S; Hata, A; Komatsu, M; Ninomaru, T1
Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S1
Baudin, E; Beaulaton, C; Blanchet, O; Chatelain, D; Do Cao, C; Ducreux, M; Faron, M; Hadoux, J; Hautefeuille, V; Hervieu, V; Hescot, S; Joubert Zakeyh, J; Kanaan, C; Laboureau, S; Leteurtre, E; Lombard-Bohas, C; Marchal, A; Perrier, M; Petorin, C; Rousselet, MC; Scoazec, JY; Tauveron, I; Walter, T1
Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F1
Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y1
Albers, D; Kasper, S; Lahner, H; Markus, P; Mende, B; Mika, S; Reis, H; Rosery, V; Schmid, KW; Schuler, M; Schumacher, B; Siveke, JT; Stuschke, M; Treckmann, J; Wiesweg, M1
Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y1
Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY1
Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD1
Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP1
Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK1
Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K1
Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P1
Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J1
Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN1
Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X1
Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A1
Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H1
Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X1
Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY1
Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J1
Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y1
Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K1
Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K1
Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y1

Reviews

10 review(s) available for platinum and etoposide

ArticleYear
[Second-line chemotherapy for recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids

2005
Systemic therapy for small cell lung cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Volume: 11, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma

2013
Current concepts in the management of small cell lung cancer.
    The Indian journal of medical research, 2013, Volume: 137, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome

2013
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
    Thoracic cancer, 2017, Volume: 8, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma

2017
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
    Respiratory investigation, 2018, Volume: 56, Issue:4

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors

2018
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
    BMC cancer, 2018, Aug-10, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma

2018
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
    ESMO open, 2021, Volume: 6, Issue:1

    Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma

2021
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chemotherapy, 2021, Volume: 66, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome

2021
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
    Anticancer research, 2023, Volume: 43, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms

2023
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
    Journal of cancer research and therapeutics, 2023, Volume: 19, Issue:Supplement

    Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma

2023

Trials

19 trial(s) available for platinum and etoposide

ArticleYear
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors

1992
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Administration, Oral; Adult; Aged; Carcinoma; Drug Resistance; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome

1994
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure

1995
[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Platinum; Uterine Cervical Neoplasms; Vindesine

1996
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies

1996
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan

2005
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 72, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome

2011
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome

2011
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome

2011
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
    British journal of cancer, 2018, 03-06, Volume: 118, Issue:5

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome

2018
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Tre
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Double-Blind Method; Etoposide; Humans; Lung Neoplasms; Picornaviridae; Platinum

2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 07-20, Volume: 38, Issue:21

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis

2020
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 149

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Patient Reported Outcome Measures; Platinum; Quality of Life

2020
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    PloS one, 2021, Volume: 16, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States

2021
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma

2022
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
    Thoracic cancer, 2022, Volume: 13, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma

2022
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum

2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
    Thoracic cancer, 2023, Volume: 14, Issue:28

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma

2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
    Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan

2023

Other Studies

65 other study(ies) available for platinum and etoposide

ArticleYear
Overview of early and investigational chemotherapeutic agents in solid tumors.
    Medical and pediatric oncology, 1976, Volume: 2, Issue:4

    Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Compounds; Camptothecin; Cycloleucine; Etoposide; Floxuridine; Humans; Neoplasms; Nitrogen Mustard Compounds; Picolinic Acids; Platinum; Porfiromycin; Streptonigrin; Teniposide; Thiotepa; Tubercidin

1976
Metastatic choriocarcinoma with coexistent term pregnancy following four recurrent consecutive moles.
    Acta obstetricia et gynecologica Scandinavica, 1992, Volume: 71, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Methotrexate; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms

1992
Clinical experiences with platinum and etoposide therapy in lung cancer.
    Oncology, 1992, Volume: 49 Suppl 1

    Topics: Etoposide; Humans; Neoplasms; Platinum

1992
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
    Cancer investigation, 1990, Volume: 8, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Platinum; Regression Analysis; Remission Induction

1990
Chemotherapeutic approaches to the treatment of testicular cancer.
    Seminars in urology, 1988, Volume: 6, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Dactinomycin; Etoposide; Humans; Male; Platinum; Prognosis; Testicular Neoplasms; Vinblastine

1988
Clinical trials in cancer medicine.
    Australian family physician, 1980, Volume: 9, Issue:1

    Topics: Adult; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Male; Methotrexate; Platinum; Tamoxifen; Teniposide; Testicular Neoplasms

1980
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Cancer, 1994, Jun-01, Volume: 73, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; DNA; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Germinoma; Humans; Leukocytes; Male; Middle Aged; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Testicular Neoplasms; Vinblastine

1994
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
    British journal of cancer, 1995, Volume: 71, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Carboplatin; Cisplatin; DNA Adducts; DNA Repair; DNA, Neoplasm; Etoposide; Humans; Kinetics; Leukocytes; Neoplasms; Platinum

1995
Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption.
    Pediatric neurosurgery, 1994, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Blood-Brain Barrier; Brain; Brain Neoplasms; Carboplatin; Cisplatin; Etoposide; Female; Germinoma; Hearing Loss, High-Frequency; Humans; Magnetic Resonance Imaging; Male; Mannitol; Platinum; Treatment Outcome

1994
Considerations on radiotherapy dose intensity for limited small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 1994, Volume: 10 Suppl 1

    Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Platinum; Radiotherapy Dosage; Time Factors

1994
Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Biochemical pharmacology, 1994, Mar-02, Volume: 47, Issue:5

    Topics: Cisplatin; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Glutathione; Humans; Male; Platinum; Teratoma; Testicular Neoplasms; Tumor Cells, Cultured

1994
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
    Cancer research, 1994, Mar-15, Volume: 54, Issue:6

    Topics: Animals; Apoptosis; Cell Division; Cell Fractionation; Cisplatin; DNA; DNA Adducts; DNA Damage; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; G2 Phase; Male; Methylprednisolone; Mitosis; Platinum; Rats; Rats, Sprague-Dawley; S Phase; Thymus Gland

1994
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
    Gynecologic oncology, 1996, Volume: 61, Issue:1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine

1996
[Comparative studies of platinum concentrations in the neck tissues of rats between intraarterial and intravenous infusion of CDDP].
    Nihon Jibiinkoka Gakkai kaiho, 2002, Volume: 105, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Neck; Platinum; Rats; Rats, Inbred F344; Tissue Distribution

2002
Topotecan as first-line therapy for small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan

2003
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
    Clinical lung cancer, 2009, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma

2009
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:6

    Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma

2010
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate

2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Platinum; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting

2012
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Endocrine-related cancer, 2012, Volume: 19, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome

2012
Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Etoposide; Female; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2012
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate

2014
Primary combined neuroendocrine carcinoma (small-cell type) and squamous cell carcinoma of the colon.
    Histopathology, 2016, Volume: 68, Issue:5

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Colon; Colonic Neoplasms; Etoposide; Fatal Outcome; Humans; Male; Platinum; Point Mutation; Proto-Oncogene Proteins p21(ras); Tomography, X-Ray Computed

2016
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Bleomycin; Case-Control Studies; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Hearing Loss; Humans; Longitudinal Studies; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Ovariectomy; Platinum; Vinblastine; Young Adult

2017
Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Male; Neoplasms, Germ Cell and Embryonal; Platinum; Remission Induction; Testicular Neoplasms; Treatment Outcome

2018
Apatinib and etoposide: surprising efficacy of an oral combination.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Etoposide; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Pyridines

2018
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 126

    Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma

2018
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2019, Feb-23, Volume: 41, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome

2019
Immunotherapy: a new era in small-cell lung cancer.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Antibodies, Monoclonal; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum

2019
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    BMC pulmonary medicine, 2019, Nov-01, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom

2019
Circulating tumor cell clusters and circulating tumor cell-derived explant models as a tool for treatment response.
    BioTechniques, 2020, Volume: 69, Issue:1

    Topics: Animals; Antineoplastic Agents; Blood Cells; Disease Progression; Etoposide; Humans; Mice, Nude; Neoplastic Cells, Circulating; Platinum; Small Cell Lung Carcinoma

2020
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tumori, 2022, Volume: 108, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Etoposide; Female; Humans; Male; Markov Chains; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma

2022
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Annals of palliative medicine, 2021, Volume: 10, Issue:1

    Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma

2021
Combination treatment options for small-cell lung cancer.
    The Lancet. Oncology, 2021, Volume: 22, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum

2021
Combination treatment options for small-cell lung cancer - Authors' reply.
    The Lancet. Oncology, 2021, Volume: 22, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum

2021
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
    American journal of clinical oncology, 2021, 05-01, Volume: 44, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate

2021
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
    Endocrine-related cancer, 2021, 06-23, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome

2021
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2021, 08-04, Volume: 19, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States

2021
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States

2021
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
    Cancer investigation, 2022, Volume: 40, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome

2022
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
    Neuroendocrinology, 2022, Volume: 112, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum

2022
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
    Cancer treatment and research communications, 2021, Volume: 29

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Progression-Free Survival; Retrospective Studies

2021
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
    Cancer medicine, 2022, Volume: 11, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms

2022
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
    Cancer medicine, 2022, Volume: 11, Issue:19

    Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma

2022
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Thoracic cancer, 2022, Volume: 13, Issue:16

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma

2022
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
    Immunotherapy, 2022, Volume: 14, Issue:13

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma

2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Endocrine-related cancer, 2022, 10-01, Volume: 29, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies

2022
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-14, Volume: 28, Issue:20

    Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment

2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
    Thoracic cancer, 2022, Volume: 13, Issue:19

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma

2022
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:8

    Topics: Etoposide; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms

2023
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Lung cancer (Amsterdam, Netherlands), 2022, Volume: 173

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome

2022
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
    Anti-cancer drugs, 2022, 11-01, Volume: 33, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma

2022
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
    Thoracic cancer, 2022, Volume: 13, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma

2022
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies

2023
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
    The Korean journal of internal medicine, 2023, Volume: 38, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma

2023
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
    Thoracic cancer, 2023, Volume: 14, Issue:15

    Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma

2023
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
    BMC cancer, 2023, Apr-06, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma

2023
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
    Journal of experimental & clinical cancer research : CR, 2023, Apr-26, Volume: 42, Issue:1

    Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma

2023
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
    Drugs & aging, 2023, Volume: 40, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma

2023
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
    Cancer medicine, 2023, Volume: 12, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies

2023
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
    Clinical lung cancer, 2023, Volume: 24, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma

2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma

2023
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma

2023
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    BMC cancer, 2023, Dec-06, Volume: 23, Issue:1

    Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma

2023